WisdomTree launches lowest price Ethereum ETP
WisdomTree, the exchange-traded product sponsor, is expanding its digital assets range with the launch of a physically-backed ether ETP.
The WisdomTree Ethereum ETP (ETHW) listed today (29 April) on Börse Xetra and SIX, the Swiss Stock Exchange.
Related articles
WisdomTree claims it now offers the lowest priced physically-backed ether and bitcoin ETPs in Europe, both with a total expense ratio of 0.95% and passported across the European Union.
WisdomTree Ethereum provides investors with a simple, secure and cost-efficient way to gain exposure to the price of ether, the native currency of the Ethereum network, while utilising the best of traditional financial infrastructure and product structuring.
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
Regulatory News:
Vifor Pharma today announced that the first patient has been enrolled in the large scale registry CARE-HK in HF (cardiovascular and renal treatment in HF patients with or at high risk for HK). This non-interventional clinical study aims to better understand renin-angiotensin-aldosterone system inhibitors (RAASi) treatment decisions in clinical practice, potential barriers to achieving optimal guideline-directed care in HF patients with or at high risk for HK, and to assess how Veltassa ® may be used in the management of this patient population.
âOne of the most pressing issues in management of chronic heart failure is that therapies that have proven to reduce the risk of death and hospitalizations, and are thus strongly recommended by the guidelines, are not optimally used in clinical practice. This is certainly the case with RAASi, which are under-used in many patients, especially those with or at high risk of hyperkalemia,â said Dr. Mikhail Kosiborod
Vifor Pharma: First patient enrolled in CARE-HK in HF to evaluate role of Veltassa (patiromer) in enabling RAASi treatment finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.